Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
GX-19
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/24/2021
ZF2001
Potential treatment - clinical evidence Experimental Vaccine Mar/24/2021
1-{3-[2-Hydroxy-3-(4-methylpiperidino)propoxy]phenoxy}-3-(4-methylpiperidino)-2-propanol
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Darapladib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Litronesib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Flumatinib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Kasugamycin
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Y-320
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Isocyclosporin A
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Cyclosporin B
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Bemcentinib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
NIM811
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Alisporivir
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
Dp44mT
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
WYE-125132
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
AZD8055
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
pCMVkan-S
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/22/2021
EK1C4
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/20/2021
EK1
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/20/2021
GS‐441524
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/19/2021